[Perspectives] The CRASH-2 randomised controlled trial: a retrospective

Trauma with subsequent death from exsanguination is a global killer. As most deaths from haemorrhage occur in the first few hours after injury, the need to treat patients as soon as possible is imperative. With more than 90% of trauma deaths occurring in low and middle-income countries, it is clear that even a moderate decrease in these high death rates could have an important impact on global health outcomes. This line of thought underpinned the work of the CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) randomised controlled trial (RCT), undertaken by the Clinical Trials Unit at the London School of Hygiene& Tropical Medicine (LSHTM).
Source: LANCET - Category: General Medicine Authors: Tags: Perspectives Source Type: research